<DOC>
	<DOCNO>NCT01346826</DOCNO>
	<brief_summary>This study aim test hypothesis accelerate infusion infliximab inferior conventional 2 hour infusion respect frequency infusion reaction .</brief_summary>
	<brief_title>Safety Accelerated Infliximab Infusions Patients With Inflammatory Bowel Disease ( IBD )</brief_title>
	<detailed_description>The standard protocol infliximab administration infusion 2 hour . However , due discomfort patient limitation medical resource , accelerate infusion desirable accelerated infusion increase frequency infusion reaction . Recent observational study show accelerated infusion infliximab 1 hour 30 minute increase frequency infusion reaction patient show infusion reaction previous 4 infusion 2 hour . However , randomized trial compare safety accelerate infusion protocol standard infusion protocol yet .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Patients receive infliximab Crohn 's disease ulcerative colitis Ethnicity : Korean Patients show infusion reaction 4 time infliximab ( 5mg/kg ) infusion 2 hour Informed consent Sever cardiopulmonary disease Allergic diseases Bronchial asthma Allergic rhinitis Atopic dermatitis Other allergic disease determine suitable study participation investigator Severe liver disease Severe renal disease Body weight 100 kg Other medical surgical disease determine suitable study participation investigator</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Crohn 's disease</keyword>
	<keyword>Ulcerative colitis</keyword>
	<keyword>Infliximab</keyword>
	<keyword>Infusion reaction</keyword>
</DOC>